Multiple Sclerosis
Literature Review
Stem cell transplant superior to DMTs for secondary progressive MS
More than 60% of patients with SPMS who received AHSCT were free from disability progression at 5 years.
Literature Review
Four-gene signature linked to increased PML risk
Investigators have identified four immune-associated genes that put immunocompromised patients at risk for progressive multifocal...
Literature Review
High drug costs exclude most neurology patients from cutting-edge treatment
“Our study of people with neurologic conditions found that fewer than 20% were being treated with new medications.”
Literature Review
New framework for MS diagnosis and treatment proposed
The new framework is based on underlying biology of disease and acknowledges the different trajectories of individual patients.
Literature Review
Advancing health equity in neurology is essential to patient care
The final plenary session at the ANA annual conference offered insights into the underlying causes of health care disparities within neurology and...
Conference Coverage
Even mild MS relapses may signal faster disability accumulation
Nondisabling relapses “should be considered in decisions to initiate or escalate treatment, including with high-efficacy therapies.”
Conference Coverage
Stem cell therapy strikes out in progressive MS
A retrospective study suggests no advantage of AHSCT over disease-modifying therapy in progressive MS.
Conference Coverage
More evidence for EBV’s role in MS
Genetic sequencing of T-cell responses suggests the possibility of an ongoing immune response.
Conference Coverage
New research confirms recommendations on COVID-19 boosters in MS
“Even MS patients whose B cells were depleted from circulation with ocrelizumab can mount immune responses to COVID-19 vaccines.”
Conference Coverage
GFAP may complement NfL as MS biomarker
GFAP is linked to progression while NfL is linked to inflammation.
Conference Coverage
Can MS be stopped early in its tracks?
Dimethyl fumarate reduced the risk of a first acute or progressive event related to CNS demyelination by more than 80%, compared with placebo.